ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND

Outer carton for 10, 20 and 50 ml vials and outer carton of multi-packs

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rominervin 10 mg/ml solution for injection for horses
romifidine hydrochloride

2. STATEMENT OF ACTIVE SUBSTANCES

romifidine hydrochloride	10 mg/ml
(equivalent to romifidine	8.76 mg)

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZE

10 ml
20 ml
50 ml
6 x 10 ml
6 x 20 ml
6 x 50 ml
10 x 10 ml
10 x 20 ml
10 x 50 ml

5. TARGET SPECIES

Horses



6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal periods(s)
Meat and offal: 6 days.
Not authorised for use in animals producing milk for human consumption.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}
Shelf life after first opening the bottle: 56 days
Once broached use by…

11. SPECIAL STORAGE CONDITIONS

Keep the vial in the outer carton in order to protect from light

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.
Supply / use: (National issue)

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.
Wilgenweg 7
3421 TV Oudewater
The Netherlands

16. MARKETING AUTHORISATION NUMBER(S)

Vm 41821/4062

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Glass vials of 10, 20 or 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rominervin 10 mg/ml solution for injection for horses
romifidine hydrochloride

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

10 mg/ml

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 ml
20 ml
50 ml

4. ROUTE(S) OF ADMINISTRATION

IV

5. WITHDRAWAL PERIOD(S)

Withdrawal periods(s)
Meat and offal: 6 days.
Not authorised for use in animals producing milk for human consumption.

6. BATCH NUMBER

Lot {number}

7. EXPIRY DATE

EXP {month/year}
Shelf life after first opening the container: 56 days
Once broached use by ……..

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

Rominervin 10 mg/ml solution for injection for horses

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Le Vet Beheer B.V.
Wilgenweg 7
3421 TV Oudewater
The Netherlands

Manufacturer responsible for batch release:
Produlab Pharma B.V.
Forellenweg 16
4941 SJ Raamsdonksveer
The Netherlands

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rominervin 10 mg/ml solution for injection for horses
romifidine hydrochloride

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains
Active substance:
Romifidine hydrochloride 10 mg
equivalent to 8.76 mg romifidine

Excipient(s):
Chlorocresol 2 mg

Clear colourless to slight yellow solution.

4. INDICATION(S)

Sedative to facilitate handling, examination, minor surgical interventions and minor procedures.
For premedication prior to administration of injectable or inhalation anaesthetics.
Romifidine can also be used with synthetic opiates (e.g. butorphanol) to provide deeper sedation/analgesia.

5. CONTRAINDICATIONS

Do not use in horses in the last month of pregnancy.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use TMP/S-containing products intravenously when horses have been sedated with romifidine.

6. ADVERSE REACTIONS

As with other veterinary medicinal products of this class, the following adverse events may occur:
- Bradycardia, which may be profound
- Benign, reversible cardiac arrhythmias (second degree AV block and to a lesser extent sino-atrial block)
- Hypotension, following a short period of hypertension
- Incoördination of the limbs/ataxia
- Sweating and increased salivation
- Hyperglycemia and diuresis
- In male horses, a reversible, partial penile prolapse can occur.
- Increased sensitivity of the hind legs (defensive movements)
- In very rare cases mild symptoms of colic, as the intestinal motility is temporarily inhibited.

Hypersensitivity may occur in very rare cases.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. Alternatively you can report via your national reporting system {national system details}

7. TARGET SPECIES

Horses.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For intravenous use. A dose range of 0.04 – 0.12 mg romifidine HCl/kg bodyweight (0.4 – 1.2 ml product/100 kg bodyweight) gives a dose-related response.

Onset of action, which is independent of dose, is 1 – 2 minutes. Maximum sedation is achieved after 5 - 10 minutes. Please see the Table below.

Recommended dose

Sedation

Dose	Depth of Sedation	Duration of Sedation
0.04 mg romifidine HCl/kg bw (i.e. **0.4 ml product/100 kg** bw)	Light	0.5 - 1 hour
0.08 mg romifidine HCl/kg bw (i.e. **0.8 ml product/100 kg** bw)	Deep	0.5 – 1.5 hours
0.12 mg romifidine HCl/kg bw (i.e. **1.2 ml product/100 kg** bw)	Deep sedation of prolonged duration	At this dose residual sedation may persist for up to 3 hours

When romifidine is used in combination with butorphanol for deeper sedation and analgesia, a dose of 0.04 mg – 0.12 mg romifidine HCl/kg bw (0.4 – 1.2 ml product per 100 kg bw) should be used followed by butorphanol.

Premedication

Premedication with ketamine for induction
When romifidine is used as premedication prior to ketamine induced anaesthesia, a dose of 0.1 mg romifidine HCl/ kg bw (1 ml product/100 kg bw) should be used followed by ketamine after 5-10 minutes.

Premedication with other agents for induction
When romifidine is used as premedication in combination with other agents such as injectable or inhalation anaesthetics, a dose of 0.04 mg – 0.08 mg romifidine HCl/kg bw (0.4 – 0.8 ml product per 100 kg bw) should be used followed by induction of anaesthesia after 5-10 minutes.

Maintenance of anaesthesia

To maintain or deepen surgical anaesthesia with romifidine/ketamine, when facilities for gaseous anaesthesia are not available, romifidine can be administered at a dose of 0.025 mg/kg romifidine HCl (0.25 ml product/100 kg bodyweight) followed immediately by ketamine intravenously (50% of the initial ketamine premedication dose). Administer the romifidine/ketamine top-up dose immediately prior to commencement of surgical incision or when signs of returning consciousness appear.

9. ADVICE ON CORRECT ADMINISTRATION

The stopper should not be punctured more than 40 times

10. WITHDRAWAL PERIOD(S)

Meat and offal: 6 days.

Not authorised for use in animals producing milk for human consumption.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Keep the vial in the outer carton in order to protect from light.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Shelf life after first opening the bottle: 56 days

12. SPECIAL WARNING(S)

Special precautions for use in animals:
Sedation with α2 agonist drugs, such as romifidine may increase the sensitivity of the hind legs to touch. Occasionally, defensive reactions, i.e. kicking, may occur even in apparently well sedated animals. The veterinary medicinal product should be used with caution in animals suffering from cariovascular or respiratory diseases, hepatic or renal insufficiency and in animals in shock.
When used as a pre-anaesthetic agent, sedation should be apparent before the induction of anaesthesia.
When the veterinary medicinal product is used as part of the anaesthetic procedure, care should be taken during the recovery phase to ensure that the horse is kept in a warm and quiet environment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In the case of accidental oral intake or self-injection, seek medical advice immediately and show the package insert to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur.
Avoid skin, eye or mucosal contact.
Wash the exposed skin immediately after exposure with large amounts of water.
Remove contaminated clothes that are in direct contact with skin.
In the case of accidental contact of the product with eyes, rinse thoroughly with fresh water. If symptoms occur, seek the advice of a physician.
If pregnant women handle the product, special caution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.

Advice to the physician:
Romifidine is an alpha2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.

Pregnancy and Lactation:
Do not use during the last month of pregnancy.

Overdose (symptoms, emergency procedures, antidotes):
Dosages up to 5 times the highest recommended dose caused transient adverse reactions, such as sweating, bradycardia, second degree atrio-ventricular heart blocks, hypotension, ataxia, hyperglycaemia and increase in diuresis.

In case of overdose, adverse reactions, as listed in section 4.6, are expected to be more severe and more frequent.
In such cases, symptomatic treatment should be initiated; an alpha-2 adrenergic antagonist may be useful in reducing such effects.

Interactions:
The sedative effect of the veterinary medicinal product may be potentiated by other psychoactive compounds, such as tranquillisers, other sedatives or morphine-like analgesics, therefore reducing the required dose of subsequent anaesthetic agents.

The concurrent intravenous use of potentiated sulphonamides with alpha2-agonists has been reported to cause cardiac arrhythmias which may be fatal. Intravenous administration of TMP/S containing products is therefore contra-indicated when horses have been sedated with romifidine.

The concomitant use of romifidine and phenothiazines (e.g. acepromazine) can result in severe hypotension.

The product should not be used in association with other substances belonging to the same pharmacological class (sympathicomimetic amines, including alpha-2-agonist, such as xylazine, detomidine..).

Incompatibilities:
Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

DD-MM-YYYY

15. OTHER INFORMATION

Pack sizes:
Cardboard box with 1 vial of 10 ml, 20 ml or 50 ml.
Multi-pack with 6 boxes each containing 1 vial of 10 ml, 20 ml or 50 ml.
Multi-pack with 10 boxes each containing 1 vial of 10 ml, 20 ml or 50 ml.

Not all pack sizes may be marketed.

Approved 03 March 2023